Cytosorbents Corp Stock

$0.80+0.00 (+0%)
Updated Apr 19, 2024
CTSO Price
Fair Value Price
Market Cap
52 Week Low
52 Week High
Dividend Yield
Gross Margin
Operating Margin
Profit Margin
Debt to Equity
Operating Cash Flow
Next Earnings
Apr 30, 2024
Next Dividend

CTSO Overview

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

Zen Score

Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CTSO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

CTSO is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CTSO is good value based on its book value relative to its share price (1.87x), compared to the US Medical Devices industry average (3.63x)
P/B vs Industry Valuation
CTSO is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more CTSO due diligence checks available for Premium users.

Be the first to know about important CTSO news, forecast changes, insider trades & much more!



CTSO fair value

Fair Value of CTSO stock based on Discounted Cash Flow (DCF)
Fair Value
Undervalued by
CTSO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

CTSO price to earnings (PE)

For valuing profitable companies with steady earnings

CTSO price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
CTSO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

CTSO's financial health

Profit margin

Net Income
Profit Margin
CTSO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CTSO's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Debt to equity
CTSO's short-term assets ($25.70M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CTSO's short-term assets ($25.70M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CTSO's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
CTSO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

CTSO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

CTSO vs Medical Device Stocks

TickerMarket Cap1d %P/EP/B

Cytosorbents Stock FAQ

What is Cytosorbents's quote symbol?

(NASDAQ: CTSO) Cytosorbents trades on the NASDAQ under the ticker symbol CTSO. Cytosorbents stock quotes can also be displayed as NASDAQ: CTSO.

If you're new to stock investing, here's how to buy Cytosorbents stock.

What is the 52 week high and low for Cytosorbents (NASDAQ: CTSO)?

(NASDAQ: CTSO) Cytosorbents's 52-week high was $4.29, and its 52-week low was $0.78. It is currently -81.31% from its 52-week high and 2.56% from its 52-week low.

How much is Cytosorbents stock worth today?

(NASDAQ: CTSO) Cytosorbents currently has 54,293,555 outstanding shares. With Cytosorbents stock trading at $0.80 per share, the total value of Cytosorbents stock (market capitalization) is $43.54M.

Cytosorbents stock was originally listed at a price of $76.25 in Aug 8, 2006. If you had invested in Cytosorbents stock at $76.25, your return over the last 17 years would have been -98.95%, for an annualized return of -23.5% (not including any dividends or dividend reinvestments).

How much is Cytosorbents's stock price per share?

(NASDAQ: CTSO) Cytosorbents stock price per share is $0.80 today (as of Apr 19, 2024).

What is Cytosorbents's Market Cap?

(NASDAQ: CTSO) Cytosorbents's market cap is $43.54M, as of Apr 20, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Cytosorbents's market cap is calculated by multiplying CTSO's current stock price of $0.80 by CTSO's total outstanding shares of 54,293,555.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.